Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million

Fineline Cube Feb 11, 2026
Company Deals

Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device

Fineline Cube Feb 11, 2026
Company Deals Digital

Takeda Enters $1.7 Billion AI Drug Discovery Partnership with Iambic Therapeutics

Fineline Cube Feb 11, 2026
Company Deals

Hemony Pharma Partners with Insud Pharma to Advance Fourth-Generation Oral Contraceptive in China

Fineline Cube Feb 10, 2026
Company Deals

Overseas Pharma Partners with South American Pharma Group on Global Extended-Release Drug Development

Fineline Cube Feb 10, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Drug

Changchun High-Tech’s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial

Fineline Cube Feb 11, 2026
Company Drug

Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder

Fineline Cube Feb 11, 2026
Company Drug

Legend Biotech’s Carvykti Files for European Approval as Second-Line MM Treatment

Fineline Cube Jan 24, 2024

GenScipt Biotech Corp. (HKG: 1548), a China-based Contract Development and Manufacturing Organization (CDMO), through its...

Company Deals

Beijing Sun-Novo and Zhejiang Anglikang Deepen Ties with New Drug Development Partnership

Fineline Cube Jan 24, 2024

Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621), a pharmaceutical company based in China, has...

Company Deals

WuXi XDC Partners with Celltrion to Support Global Development and Manufacturing of Bioconjugated Drugs

Fineline Cube Jan 24, 2024

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Company Drug

Visirna Therapeutics Completes Enrollment in Phase III Study for FCS Drug VSA001

Fineline Cube Jan 24, 2024

Visirna Therapeutics, a Shanghai-based biopharmaceutical company, has announced the completion of patient enrollment in a...

Company Deals

Shanghai Pharmaceutical and Sino Biopharmaceutical Form Strategic Partnership for Pharmaceutical Services

Fineline Cube Jan 24, 2024

Shanghai Pharmaceutical Co., Ltd (SPH, SHA: 601607, HKG: 2607), a leading pharmaceutical company based in...

Company

J&J Reports Q4 and Full-Year 2023 Results with Strong MedTech and Pharmaceutical Growth

Fineline Cube Jan 24, 2024

Johnson & Johnson (J&J; NYSE: JNJ), a US major, has released its financial results for...

Company Medical Device

Establishment Labs Launches Motiva Breast Implants in China

Fineline Cube Jan 23, 2024

Establishment Labs Holdings Inc., (NASDAQ: ESTA), a US-based medical technology company specializing in women’s health,...

Company

Jiuzhou Pharmaceutical Expands with $42 Million Investment in Japanese CRO Services

Fineline Cube Jan 23, 2024

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456), a Chinese pharmaceutical company, has declared plans to...

Company Medical Device

Zylox-Tonbridge Medical Technology Secures NMPA Nod for Innovative Iliac Vein Stent System

Fineline Cube Jan 23, 2024

Zylox-Tonbridge Medical Technology (HKG: 2190), a leading developer of nerve and peripheral vascular interventional devices...

Company Drug

Eisai’s Uric Acid Excretion Drug Urece Accepted for Review in China

Fineline Cube Jan 23, 2024

The Center for Drug Evaluation (CDE) in China has indicated on its website that it...

Company Drug

Hansoh Pharmaceutical Gets NMPA Approval for Type 2 Diabetes and Obesity Drug Trial

Fineline Cube Jan 23, 2024

Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a leading Chinese pharmaceutical company, has announced that...

Company Medical Device

Jiangsu Wuzhong Pharmaceutical’s Aesthetics Subsidiary Wins Approval for Facial Filler in China

Fineline Cube Jan 23, 2024

Jiangsu Wuzhong Pharmaceutical Group Corp., (SHA: 600200), a prominent player in the Chinese pharmaceutical industry,...

Company Medical Device

Lepu Medical Technology Gains NMPA Approval for Innovative Coronary Device

Fineline Cube Jan 23, 2024

Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading Chinese provider of cardiovascular disease...

Company

LifeShield Medical Launches China HQ and Advanced Heart System Factory in Suzhou

Fineline Cube Jan 23, 2024

LifeShield Medical, a leading Sino-German multinational medical device company, has announced the official operation of...

Company Deals Digital Policy / Regulatory

Tencent’s WeDoctor Teams Up with Guiyang for Digital Health Community Initiative

Fineline Cube Jan 23, 2024

The municipal government of Guiyang has entered into a strategic partnership with WeDoctor Holdings Ltd,...

Company Deals

Sandoz Strikes Deal to Acquire Coherus Biosimilar for Ophthalmic Treatment

Fineline Cube Jan 23, 2024

Swiss pharmaceutical company Sandoz (SWX: SDZ) has entered into an agreement to purchase Cimerli (ranibizumab),...

Company Drug

HuidaGene Therapeutics’ CRISPR Therapy Earns Orphan Drug Status for Duchenne Muscular Dystrophy

Fineline Cube Jan 23, 2024

China-based biotechnology company HuidaGene Therapeutics has announced that it has received Orphan Drug Designation (ODD)...

Policy / Regulatory

Pudong New Area Aims to Boost Healthcare with Comprehensive Reform Plan

Fineline Cube Jan 23, 2024

The General Office of the CPC Central Committee and State Council has released the “Implementation...

Company Drug

AstraZeneca Wins FDA Nod for Airsupra in Asthma Treatment

Fineline Cube Jan 23, 2024

AstraZeneca (AZ; NASDAQ: AZN), a leading UK pharmaceutical company, announced this week that it has...

Company Drug

Gilead’s Trodelvy Misses Primary Endpoint in Late-Stage NSCLC Trial

Fineline Cube Jan 23, 2024

Gilead Sciences (NASDAQ: GILD) has announced that a late-stage trial for its antibody-drug conjugate (ADC)...

Posts pagination

1 … 367 368 369 … 622

Recent updates

  • China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million
  • Changchun High-Tech’s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial
  • Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder
  • Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device
  • Eisai Biogen’s LEQEMBI Subcutaneous Autoinjector Wins NMPA Priority Review in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million

Company Drug

Changchun High-Tech’s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial

Company Drug

Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder

Company Deals

Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.